BeyondSpring (NASDAQ:BYSI) Stock Price Down 7.3% – Should You Sell?

Shares of BeyondSpring Inc. (NASDAQ:BYSI) fell 7.3% during trading on Tuesday . The company traded as low as $1.66 and last traded at $1.66. 8,619 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 22,125 shares. The stock had previously closed at $1.79.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of BeyondSpring in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

BeyondSpring Trading Down 7.3%

The stock has a market capitalization of $68.26 million, a price-to-earnings ratio of -11.86 and a beta of 0.43. The firm has a 50-day moving average of $1.61 and a 200 day moving average of $1.61.

BeyondSpring (NASDAQ:BYSI) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.49.

Institutional Trading of BeyondSpring

A hedge fund recently bought a new stake in BeyondSpring stock. State Street Corp purchased a new position in BeyondSpring Inc. (NASDAQ:BYSI) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned approximately 0.57% of BeyondSpring as of its most recent filing with the Securities & Exchange Commission. 40.29% of the stock is currently owned by hedge funds and other institutional investors.

BeyondSpring Company Profile

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.